+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Fanconi Anemia Epidemiology Forecast 2025-2034

  • PDF Icon

    Report

  • 150 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102571
Fanconi anemia (FA) refers to an inherited DNA repair disorder that can result in solid tumors, bone marrow failure, and/or leukemia. In the United States, the incidence rate of Fanconi anemia is around 1 in 131,000 births. It occurs almost equally in both men and women.

Fanconi Anemia Epidemiology Forecast Report Coverage

The “Fanconi Anemia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Fanconi anemia. It projects the future incidence and prevalence rates of Fanconi anemia across various populations. The study covers age and type as major determinants of the Fanconi anemia-affected population. The report highlights patterns in the prevalence of Fanconi anemia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of fanconi anemia in the 8 major markets.

Regions Covered

  • The United States
  • Germany
  • France
  • Italy
  • Spain
  • The United Kingdom
  • Japan
  • India

Fanconi Anemia: Disease Overview

Fanconi anemia is a rare genetic disease that affects the bone marrow and other parts of the body. It causes the bone marrow to produce abnormal or fewer blood cells, which may lead to aplastic anemia. Fanconi anemia patients are prone to developing solid tumors, leukemia, and myelodysplastic syndrome. The disease can also cause developmental abnormalities such as oddly shaped thumbs or microcephaly. Other symptoms may include skin patches and hearing loss.

Fanconi Anemia: Treatment Overview

The standard treatment for Fanconi anemia is a bone marrow transplant that can help in addressing blood count problems. Hormone therapy such as androgens (oxymetholone) is used to increase the number of red blood cells and platelets. Erythropoietin, G-CSF, and GM-CSF are some of the medications prescribed for improving blood count. For correcting physical abnormalities or repairing damaged organs, surgical procedures are often recommended by the healthcare provider.

Epidemiology

The Fanconi anemia epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Fanconi anemia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Fanconi anemia and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.
  • As per Fanconi Anemia Research Fund, the incidence rate of Fanconi anemia is approximately 1 in 131,000 births in the United States. It occurs almost equally in men and women. Further, 23 different genes can cause the disease, with the three most common genes being FANCA, FANCC, and FANCG.
  • Research shows that Fanconi anemia is found in all races. The incidence rate is reported to be higher in South Africans, Spanish Gitanos, and sub-Saharan Africans, with the estimated rate to be 1 in 40,000 births.
  • In the United States, around 1 in 181 people are estimated to carry a mutation in an FA gene. Moreover, it is observed that nearly 75% of individuals with Fanconi anemia have physical anomalies at birth.
  • According to the Orphanet, the expected prevalence of Fanconi anemia is estimated to be at least 1 in 160,000 births.

Country-wise Fanconi Anemia Epidemiology

The Fanconi anemia epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Fanconi anemia varies significantly between countries owing to the differences in genetic diversity, consanguinity rates, and population-specific founder mutations. In the United States, about 31 babies are born with Fanconi anemia annually, according to the Fanconi Anemia Research Fund.

Scope of the Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Fanconi anemia based on several factors.
  • Fanconi Anemia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The report helps to identify the patient population, and the unmet needs of Fanconi anemia are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

  • What are the key findings of Fanconi anemia epidemiology in the 8 major markets?
  • What will be the total number of patients with Fanconi anemia across the 8 major markets during the forecast period?
  • What was the country-wise prevalence of Fanconi anemia in the 8 major markets in the historical period?
  • Which country will have the highest number of Fanconi anemia patients during the forecast period of 2025-2034?
  • Which key factors would influence the shift in the patient population of Fanconi anemia during the forecast period of 2025-2034?
  • What are the currently available treatments for Fanconi anemia?
  • What are the disease risks, signs, symptoms, and unmet needs of Fanconi anemia?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Fanconi Anemia Market Overview - 8 MM
3.1 Fanconi Anemia Market Historical Value (2018-2024)
3.2 Fanconi Anemia Market Forecast Value (2025-2034)
4 Fanconi Anemia Epidemiology Overview - 8 MM
4.1 Fanconi Anemia Epidemiology Scenario (2018-2024)
4.2 Fanconi Anemia Epidemiology Forecast
5 Disease Overview
5.1 Signs and Symptoms
5.2 Causes
5.3 Risk Factors
5.4 Guidelines and Stages
5.5 Pathophysiology
5.6 Screening and Diagnosis
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
7 Epidemiology Scenario and Forecast - 8 MM
7.1 Key Findings
7.2 Assumptions and Rationale
7.3 Fanconi Anemia Epidemiology Scenario in 8MM (2018-2034)
8 Epidemiology Scenario and Forecast: United States
8.1 Fanconi Anemia Epidemiology Scenario and Forecast in the United States (2018-2034)
9 Epidemiology Scenario and Forecast: United Kingdom
9.1 Fanconi Anemia Epidemiology Scenario and Forecast in United Kingdom (2018-2034)
10 Epidemiology Scenario and Forecast: Germany
10.1 Fanconi Anemia Epidemiology Scenario and Forecast in Germany (2018-2034)
11 Epidemiology Scenario and Forecast: France
11.1 Fanconi Anemia Epidemiology Scenario and Forecast in France
12 Epidemiology Scenario and Forecast: Italy
12.1 Fanconi Anemia Epidemiology Scenario and Forecast in Italy (2018-2034)
13 Epidemiology Scenario and Forecast: Spain
13.1 Fanconi Anemia Epidemiology Scenario and Forecast in Spain (2018-2034)
14 Epidemiology Scenario and Forecast: Japan
14.1 Fanconi Anemia Epidemiology Scenario and Forecast in Japan (2018-2034)
15 Epidemiology Scenario and Forecast: India
15.1 Fanconi Anemia Epidemiology Scenario and Forecast in India (2018-2034)
16 Patient Journey17 Treatment Challenges and Unmet Needs18 Key Opinion Leaders (KOL) Insights